MIRA
INFORM REPORT
|
Report Date : |
22.03.2012 |
IDENTIFICATION DETAILS
|
Name : |
SANOFI |
|
|
|
|
Registered Office : |
82, Avenue Raspail Gentilly, 94250 |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2010 |
|
|
|
|
Date of Incorporation : |
15.01.1973 |
|
|
|
|
Com. Reg. No.: |
775662257 |
|
|
|
|
Legal Form : |
Public Subsidiary |
|
|
|
|
Line of Business : |
Manufacture of pharmaceutical preparations |
|
|
|
|
No. of Employees : |
5,607 |
RATING & COMMENTS
|
MIRAs Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Status : |
Good |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List September 30, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name and address
Sanofi Winthrop
Industrie
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||
Business
Description
|
Sanofi Winthrop Industrie is primarily engaged in production of
medicinally active substances to be used for their pharmacological properties
in the manufacture of medicaments; and processing of blood. This class also
includes: manufacture of chemically pure sugars; and processing of glands and
manufacture of extracts of glands, etc. |
Industry
|
Industry |
Biotechnology and Drugs |
|
ANZSIC 2006: |
1841 - Human Pharmaceutical and Medicinal
Product Manufacturing |
|
NACE 2002: |
2442 - Manufacture of pharmaceutical
preparations |
|
NAICS 2002: |
325412 - Pharmaceutical Preparation
Manufacturing |
|
UK SIC 2003: |
24421 - Manufacture of medicaments |
|
US SIC 1987: |
2834 - Pharmaceutical Preparations |
Key Executives
|
1 - Profit &
Loss Item Exchange Rate: USD 1 = EUR 0.7550783
2 - Balance Sheet Item Exchange Rate: USD 1 = EUR 0.7454064
Corporate Overview
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Corporate Structure News
|
Sanofi Winthrop
Industrie |
|
|
|
|
|
|
|
|
Company Name |
Company Type |
Location |
Country |
Industry |
Sales |
Employees |
|
|
Parent |
Paris |
France |
Biotechnology and Drugs |
48,746.5 |
113,719 |
||
|
Acquisition of Pluromed, Inc. proposed/announced.See corporate
structure news on Sanofi SA for details |
|||||||
|
Subsidiary |
Frankfurt |
Germany |
Commercial Banks |
|
17,023 |
|
|
|
Subsidiary |
Frankfurt Am Main, Hessen |
Germany |
Real Estate Operations |
|
14 |
|
|
|
Subsidiary |
Frankfurt Am Main, Hessen |
Germany |
Chemicals - Plastics and Rubber |
|
3 |
|
|
|
Subsidiary |
Frankfurt Am Main, Hessen |
Germany |
Commercial Banks |
|
2 |
|
|
|
Subsidiary |
Tokyo |
Japan |
Personal and Household Products |
875.0 |
|
|
|
|
Subsidiary |
Beijing |
China |
Miscellaneous Financial Services |
125.0 |
|
|
|
|
Subsidiary |
Frankfurt |
Germany |
Biotechnology and Drugs |
5,891.5 |
10,000 |
|
|
|
Subsidiary |
KΓΆln, Nordrhein-Westfalen |
Germany |
Biotechnology and Drugs |
177.7 |
400 |
|
|
|
Subsidiary |
MΓΌnchen, Bayern |
Germany |
Biotechnology and Drugs |
|
45 |
|
|
|
Subsidiary |
Quito |
Ecuador |
Biotechnology and Drugs |
75.0 |
|
|
|
|
Subsidiary |
Cambridge, MA |
United States |
Biotechnology and Drugs |
4,048.7 |
10,000 |
|
|
|
Subsidiary |
New York, NY |
United States |
Healthcare Facilities |
188.1 |
1,136 |
|
|
|
Branch |
New York, NY |
United States |
Healthcare Facilities |
115.8 |
600 |
|
|
|
Subsidiary |
Waterford |
Ireland |
Biotechnology and Drugs |
1,097.3 |
453 |
|
|
|
Subsidiary |
Geel |
Belgium |
Biotechnology and Drugs |
281.1 |
446 |
|
|
|
Branch |
Cambridge, MA |
United States |
Biotechnology and Drugs |
285.6 |
300 |
|
|
|
Subsidiary |
SΓ£o Paulo , SΓ£o Paulo |
Brazil |
Miscellaneous Capital Goods |
35.0 |
200 |
|
|
|
Subsidiary |
Waltham, MA |
United States |
Biotechnology and Drugs |
|
200 |
|
|
|
Subsidiary |
Ridgefield, NJ |
United States |
Biotechnology and Drugs |
77.7 |
150 |
|
|
|
Branch |
Waltham, MA |
United States |
Biotechnology and Drugs |
90.4 |
95 |
|
|
|
Division |
Framingham, MA |
United States |
Biotechnology and Drugs |
|
95 |
|
|
|
Subsidiary |
Langley, BC |
Canada |
Biotechnology and Drugs |
|
88 |
|
|
|
Branch |
Middleton, WI |
United States |
Biotechnology and Drugs |
66.6 |
70 |
|
|
|
Subsidiary |
Cambridge, MA |
United States |
Business Services |
6.7 |
50 |
|
|
|
Division |
Cambridge, MA |
United States |
Scientific and Technical Instruments |
|
3 |
|
|
|
Subsidiary |
Naarden, Noord-Holland |
Netherlands |
Personal and Household Products |
984.4 |
|
|
|
|
Subsidiary |
Oxford |
United Kingdom |
Personal and Household Products |
135.0 |
205 |
|
|
|
Subsidiary |
Neu-Isenburg |
Germany |
Personal and Household Products |
186.8 |
200 |
|
|
|
Subsidiary |
Neu-Isenburg, Hessen |
Germany |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Modena, Modena |
Italy |
Personal and Household Products |
151.7 |
131 |
|
|
|
Subsidiary |
Porto Salvo |
Portugal |
Personal and Household Products |
34.7 |
37 |
|
|
|
Subsidiary |
Neu-Isenburg, Hessen |
Germany |
Biotechnology and Drugs |
|
27 |
|
|
|
Subsidiary |
Tokyo |
Japan |
Biotechnology and Drugs |
1.0 |
|
|
|
|
Subsidiary |
Johannesburg |
South Africa |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Dubai |
United Arab Emirates |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Chilly Mazarin |
France |
Biotechnology and Drugs |
1,783.9 |
6,777 |
|
|
|
Subsidiary |
Amsterdam |
Netherlands |
Biotechnology and Drugs |
564.3 |
6,000 |
|
|
|
Subsidiary |
Hlohovec |
Slovakia |
Biotechnology and Drugs |
243.2 |
996 |
|
|
|
Subsidiary |
Kyiv |
Ukraine |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Praha |
Czech Republic |
Biotechnology and Drugs |
407.0 |
6,000 |
|
|
|
Subsidiary |
Bucharest |
|
Biotechnology and Drugs |
84.4 |
544 |
|
|
|
Subsidiary |
Duluth, GA |
United States |
Fish and Livestock |
2,700.0 |
5,600 |
|
|
|
Subsidiary |
Harlow |
United Kingdom |
Biotechnology and Drugs |
2,411.0 |
5,235 |
|
|
|
Subsidiary |
Harlow |
United Kingdom |
Personal and Household Products |
108.5 |
192 |
|
|
|
Subsidiary |
Parramatta, NSW |
Australia |
Medical Equipment and Supplies |
69.1 |
95 |
|
|
|
Subsidiary |
Manukau |
New Zealand |
Medical Equipment and Supplies |
2.9 |
39 |
|
|
|
Subsidiary |
Tokyo |
Japan |
Medical Equipment and Supplies |
|
|
|
|
|
Subsidiary |
Lyon |
France |
Biotechnology and Drugs |
963.7 |
1,792 |
|
|
|
Subsidiary |
St Herblon |
France |
Biotechnology and Drugs |
32.5 |
108 |
|
|
|
Subsidiary |
Hallbergmoos, Bayern |
Germany |
Personal and Household Products |
75.9 |
100 |
|
|
|
Subsidiary |
Rio De Mouro |
Portugal |
Personal and Household Products |
16.7 |
26 |
|
|
|
Subsidiary |
Velserbroek, Noord-Holland |
Netherlands |
Biotechnology and Drugs |
28.3 |
23 |
|
|
|
Branch |
Athens, GA |
United States |
Biotechnology and Drugs |
247.5 |
260 |
|
|
|
Subsidiary |
Gainesville, GA |
United States |
Biotechnology and Drugs |
|
250 |
|
|
|
Subsidiary |
Duluth, GA |
United States |
Fish and Livestock |
75.0 |
225 |
|
|
|
Subsidiary |
El Marques, Queretaro |
Mexico |
Miscellaneous Capital Goods |
5.0 |
200 |
|
|
|
Subsidiary |
Nanchang City, Jiang Xi |
China |
Crops |
23.0 |
170 |
|
|
|
Subsidiary |
Assago, Milano |
Italy |
Chemical Manufacturing |
180.3 |
164 |
|
|
|
Subsidiary |
Halfway House |
South Africa |
Biotechnology and Drugs |
37.0 |
100 |
|
|
|
Subsidiary |
Bogota, Cundinamarca |
Colombia |
Miscellaneous Capital Goods |
35.0 |
100 |
|
|
|
Subsidiary |
Campinas , SΓ£o Paulo |
Brazil |
Crops |
35.0 |
100 |
|
|
|
Subsidiary |
Pasig , Metro Manila |
Philippines |
Biotechnology and Drugs |
8.0 |
100 |
|
|
|
Subsidiary |
Barcelona |
Spain |
Retail (Specialty) |
58.5 |
58 |
|
|
|
Subsidiary |
Buenos Aires, Buenos Aires |
Argentina |
Crops |
2.0 |
50 |
|
|
|
Subsidiary |
Singapore |
Singapore |
Crops |
15.0 |
35 |
|
|
|
Subsidiary |
Bruxelles |
Belgium |
Food Processing |
25.2 |
27 |
|
|
|
Subsidiary |
Antony |
France |
Biotechnology and Drugs |
31.8 |
4,593 |
|
|
|
Subsidiary |
Paris |
France |
Chemical Manufacturing |
|
|
|
|
|
Subsidiary |
Paris |
France |
Biotechnology and Drugs |
1,405.2 |
3,499 |
|
|
|
Subsidiary |
Paris |
France |
Biotechnology and Drugs |
3,565.2 |
3,358 |
|
|
|
Subsidiary |
Strasbourg |
France |
Biotechnology and Drugs |
|
75,000 |
|
|
|
Subsidiary |
Compiègne |
France |
Biotechnology and Drugs |
450.0 |
|
|
|
|
Subsidiary |
Shinjuku-Ku, Tokyo |
Japan |
Biotechnology and Drugs |
1,750.0 |
3,000 |
|
|
|
Subsidiary |
Budapest |
Hungary |
Biotechnology and Drugs |
1,542.6 |
2,500 |
|
|
|
Subsidiary |
Maharashtra |
India |
Miscellaneous Capital Goods |
90.0 |
2,450 |
|
|
|
Subsidiary |
MΓ©xico, D.F. |
Mexico |
Biotechnology and Drugs |
862.8 |
2,425 |
|
|
|
Subsidiary |
Mumbai |
India |
Biotechnology and Drugs |
293.5 |
2,282 |
|
|
|
Subsidiary |
Mumbai (Bombay), Maharashtra |
India |
Biotechnology and Drugs |
|
400 |
|
|
|
Recently acquired (previously owned by Universal Medicare Ltd ).See corporate
structure news on Sanofi SA for details |
|||||||
|
Subsidiary |
SΓ£o Paulo, SP |
Brazil |
Biotechnology and Drugs |
1,900.0 |
2,250 |
|
|
|
Subsidiary |
Istanbul, Istanbul |
Turkey |
Biotechnology and Drugs |
621.0 |
2,000 |
|
|
|
Branch |
Anthony |
France |
Biotechnology and Drugs |
40.0 |
2,000 |
|
|
|
Subsidiary |
Campinas, SP |
Brazil |
Biotechnology and Drugs |
1,607.7 |
1,615 |
|
|
|
Subsidiary |
Barcelona |
Spain |
Biotechnology and Drugs |
999.6 |
1,550 |
|
|
|
Subsidiary |
Dhaka |
Bangladesh |
Biotechnology and Drugs |
|
1,200 |
|
|
|
Subsidiary |
Plymouth Meeting, PA |
United States |
Biotechnology and Drugs |
146.9 |
1,198 |
|
|
|
Recently acquired (previously owned by BMP Sunstone Corp.).See corporate
structure news on Sanofi SA for details |
|||||||
|
Subsidiary |
Macquarie Park, NSW |
Australia |
Biotechnology and Drugs |
597.8 |
1,000 |
|
|
|
Subsidiary |
Frankfurt |
Germany |
Miscellaneous Capital Goods |
388.0 |
1,000 |
|
|
|
Subsidiary |
Damascus |
Syria |
Biotechnology and Drugs |
27.3 |
25 |
|
|
|
Subsidiary |
SΓ£o Paulo , SΓ£o Paulo |
Brazil |
Miscellaneous Capital Goods |
350.0 |
1,000 |
|
|
|
Subsidiary |
Laval, QC |
Canada |
Biotechnology and Drugs |
1,170.4 |
800 |
|
|
|
Subsidiary |
St Laurent, QC |
Canada |
Biotechnology and Drugs |
117.2 |
51 |
|
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Biotechnology and Drugs |
277.6 |
774 |
|
|
|
Subsidiary |
Karachi |
Pakistan |
Biotechnology and Drugs |
88.2 |
756 |
|
|
|
Subsidiary |
Midrand |
South Africa |
Biotechnology and Drugs |
150.0 |
750 |
|
|
|
Subsidiary |
Jakarta |
Indonesia |
Biotechnology and Drugs |
60.0 |
750 |
|
|
|
Subsidiary |
Warszawa |
Poland |
Biotechnology and Drugs |
595.7 |
732 |
|
|
|
Subsidiary |
Cairo |
Egypt |
Biotechnology and Drugs |
|
716 |
|
|
|
Subsidiary |
Legaspi Village, Makati , Metro Manila |
Philippines |
Biotechnology and Drugs |
8.0 |
600 |
|
|
|
Subsidiary |
New York, NY |
United States |
Biotechnology and Drugs |
|
600 |
|
|
|
Subsidiary |
Shanghai |
China |
Biotechnology and Drugs |
30.0 |
575 |
|
|
|
Subsidiary |
Chattanooga, TN |
United States |
Biotechnology and Drugs |
463.3 |
500 |
|
|
|
Subsidiary |
Mississauga, ON |
Canada |
Chemical Manufacturing |
20.3 |
11 |
|
|
|
Subsidiary |
Casablanca |
Morocco |
Biotechnology and Drugs |
107.0 |
450 |
|
|
|
Subsidiary |
Casablanca |
Morocco |
Biotechnology and Drugs |
|
450 |
|
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Personal and Household Products |
317.9 |
425 |
|
|
|
Subsidiary |
Porto Salvo |
Portugal |
Biotechnology and Drugs |
156.6 |
405 |
|
|
|
Subsidiary |
Virginia, QLD |
Australia |
Biotechnology and Drugs |
29.2 |
400 |
|
|
|
Subsidiary |
San Isidro, Buenos Aires |
Argentina |
Biotechnology and Drugs |
109.3 |
362 |
|
|
|
Subsidiary |
Moscow |
Russian Federation |
Biotechnology and Drugs |
90.0 |
350 |
|
|
|
Subsidiary |
Jeddah, Makkah |
Saudi Arabia |
Biotechnology and Drugs |
60.0 |
350 |
|
|
|
Subsidiary |
Ho Chi Minh City |
Viet Nam |
Biotechnology and Drugs |
12.0 |
350 |
|
|
|
Subsidiary |
Megrine |
Tunisia |
Biotechnology and Drugs |
|
315 |
|
|
|
Subsidiary |
Meyrin |
Switzerland |
Personal and Household Products |
75.0 |
270 |
|
|
|
Subsidiary |
West Malling |
United Kingdom |
Biotechnology and Drugs |
85.0 |
265 |
|
|
|
Subsidiary |
Diegem |
Belgium |
Biotechnology and Drugs |
339.9 |
257 |
|
|
|
Subsidiary |
MΓ©xico |
Mexico |
Healthcare Facilities |
20.0 |
250 |
|
|
|
Subsidiary |
MΓΌlheim-KΓ€rlich, Rheinland-Pfalz |
Germany |
Biotechnology and Drugs |
158.2 |
227 |
|
|
|
Subsidiary |
Petaling Jaya, Selangor |
Malaysia |
Biotechnology and Drugs |
63.7 |
200 |
|
|
|
Subsidiary |
Budapest |
Hungary |
Biotechnology and Drugs |
30.0 |
200 |
|
|
|
Subsidiary |
Istanbul |
Turkey |
Biotechnology and Drugs |
621.0 |
185 |
|
|
|
Subsidiary |
Wien DC |
Austria |
Biotechnology and Drugs |
175.6 |
175 |
|
|
|
Subsidiary |
Beirut |
Lebanon |
Biotechnology and Drugs |
75.0 |
150 |
|
|
|
Subsidiary |
Bromma |
Sweden |
Personal and Household Products |
195.2 |
144 |
|
|
|
Subsidiary |
Budapest |
Hungary |
Biotechnology and Drugs |
|
140 |
|
|
|
Subsidiary |
Singapore |
Singapore |
Biotechnology and Drugs |
1,018.5 |
131 |
|
|
|
Subsidiary |
Dublin |
Ireland |
Biotechnology and Drugs |
105.7 |
102 |
|
|
|
Subsidiary |
BogotΓ‘ DC |
Colombia |
Personal and Household Products |
179.8 |
100 |
|
|
|
Subsidiary |
Sofia |
Bulgaria |
Biotechnology and Drugs |
39.0 |
100 |
|
|
|
Subsidiary |
In Lamas Urbanizacion La Castellana, Caracas |
Venezuela |
Miscellaneous Capital Goods |
30.0 |
100 |
|
|
|
Subsidiary |
Causeway Bay |
Hong Kong |
Personal and Household Products |
18.0 |
100 |
|
|
|
Subsidiary |
Las Condes, Santiago |
Chile |
Biotechnology and Drugs |
8.0 |
100 |
|
|
|
Subsidiary |
Dublin |
Ireland |
Biotechnology and Drugs |
83.4 |
88 |
|
|
|
Subsidiary |
Dublin |
Ireland |
Personal and Household Products |
29.1 |
22 |
|
|
|
Subsidiary |
Lima |
Peru |
Personal and Household Products |
25.0 |
87 |
|
|
|
Subsidiary |
Horsholm |
Denmark |
Biotechnology and Drugs |
71.0 |
85 |
|
|
|
Subsidiary |
Dakar |
Senegal |
Personal and Household Products |
|
80 |
|
|
|
Subsidiary |
Amman |
Jordan |
Biotechnology and Drugs |
27.0 |
70 |
|
|
|
Subsidiary |
Hong Kong, Hong Kong |
Hong Kong |
Non-Metallic Mining |
|
60 |
|
|
|
Subsidiary |
Lysaker, Akershus |
Norway |
Biotechnology and Drugs |
70.3 |
54 |
|
|
|
Subsidiary |
Paris |
France |
Personal and Household Products |
70.4 |
50 |
|
|
|
Subsidiary |
Taipei |
Taiwan |
Personal and Household Products |
22.5 |
50 |
|
|
|
Subsidiary |
Vilnius |
Lithuania |
Biotechnology and Drugs |
2.0 |
50 |
|
|
|
Subsidiary |
San Diego, CA |
United States |
Biotechnology and Drugs |
21.4 |
46 |
|
|
|
Subsidiary |
Taipei City, Taipei City |
Taiwan |
Biotechnology and Drugs |
1.0 |
46 |
|
|
|
Subsidiary |
Singapore |
Singapore |
Biotechnology and Drugs |
94.9 |
39 |
|
|
|
Subsidiary |
Orlando, FL |
United States |
Business Services |
|
30 |
|
|
|
Subsidiary |
Montevideo |
Uruguay |
Retail (Drugs) |
|
30 |
|
|
|
Subsidiary |
Paris |
France |
Biotechnology and Drugs |
0.0 |
28 |
|
|
|
Subsidiary |
South San Francisco, CA |
United States |
Business Services |
|
20 |
|
|
|
Subsidiary |
St Germain En Laye |
France |
Personal and Household Products |
261.1 |
14 |
|
|
|
Subsidiary |
Lyon |
France |
Biotechnology and Drugs |
189.5 |
224 |
|
|
|
Subsidiary |
Riga |
Latvia |
Biotechnology and Drugs |
2.0 |
14 |
|
|
|
Subsidiary |
Frankfurt Am Main, Hessen |
Germany |
Commercial Banks |
|
2 |
|
|
|
Subsidiary |
Paris |
France |
Personal and Household Products |
1,267.3 |
|
|
|
|
Subsidiary |
Moscow |
Russian Federation |
Personal and Household Products |
682.2 |
|
|
|
|
Subsidiary |
Geneva |
Switzerland |
Biotechnology and Drugs |
450.0 |
|
|
|
|
Subsidiary |
MΓ©xico DF, Federal District |
Mexico |
Biotechnology and Drugs |
250.0 |
|
|
|
|
Subsidiary |
San Isidro |
Argentina |
Biotechnology and Drugs |
75.0 |
|
|
|
|
Subsidiary |
Tegucigalpa |
Honduras |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Manama |
Bahrain |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Commercial Banks |
|
|
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Personal and Household Products |
|
|
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Commercial Banks |
|
|
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Commercial Banks |
|
|
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Personal and Household Products |
739.4 |
785 |
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Biotechnology and Drugs |
77.6 |
30 |
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Biotechnology and Drugs |
2,081.2 |
420 |
|
|
|
Subsidiary |
Newcastle Upon Tyne |
United Kingdom |
Biotechnology and Drugs |
103.0 |
390 |
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Business Services |
|
|
|
|
|
Subsidiary |
Quito |
Ecuador |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Dubai |
United Arab Emirates |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Prague |
Czech Republic |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Jakarta |
Indonesia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Warsaw |
Poland |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Bratislava |
Slovakia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Goa |
India |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Macquarie Park, NSW |
Australia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Caracas |
Venezuela |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Antony |
France |
Personal and Household Products |
|
|
|
|
|
Subsidiary |
Lyon |
France |
Biotechnology and Drugs |
2,048.5 |
4,500 |
|
|
|
Subsidiary |
Swiftwater, PA |
United States |
Biotechnology and Drugs |
554.0 |
8,500 |
|
|
|
Subsidiary |
Marcy |
France |
Healthcare Facilities |
|
1,300 |
|
|
|
Subsidiary |
SΓ£o Paulo , SΓ£o Paulo |
Brazil |
Miscellaneous Capital Goods |
150.0 |
750 |
|
|
|
Subsidiary |
Chaoyang District, Beijing |
China |
Miscellaneous Capital Goods |
102.0 |
350 |
|
|
|
Subsidiary |
Istanbul, Istanbul |
Turkey |
Biotechnology and Drugs |
30.0 |
100 |
|
|
|
Subsidiary |
Las Condes, Santiago |
Chile |
Biotechnology and Drugs |
29.0 |
100 |
|
|
|
Subsidiary |
Legaspi Village, Makati , Metro Manila |
Philippines |
Biotechnology and Drugs |
27.0 |
100 |
|
|
|
Subsidiary |
Moscow |
Russian Federation |
Biotechnology and Drugs |
27.0 |
100 |
|
|
|
Subsidiary |
Lumpini, Pathumwan, Bangkok |
Thailand |
Biotechnology and Drugs |
27.0 |
100 |
|
|
|
Subsidiary |
Jakarta |
Indonesia |
Biotechnology and Drugs |
24.0 |
100 |
|
|
|
Subsidiary |
Ciudad de MΓ©xico |
Mexico |
Biotechnology and Drugs |
|
65 |
|
|
|
Branch |
Bogota, Cundinamarca |
Colombia |
Biotechnology and Drugs |
15.0 |
55 |
|
|
|
Subsidiary |
SΓ£o Paulo, SP |
Brazil |
Biotechnology and Drugs |
|
50 |
|
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Personal and Household Products |
26.9 |
35 |
|
|
|
Subsidiary |
Abidjan |
Cote d'Ivoire |
Personal and Household Products |
|
26 |
|
|
|
Subsidiary |
Brunn am Gebirge |
Austria |
Personal and Household Products |
17.6 |
25 |
|
|
|
Subsidiary |
West Toronto, ON |
Canada |
Biotechnology and Drugs |
|
10 |
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Commercial Banks |
|
2 |
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Biotechnology and Drugs |
11.3 |
2 |
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Guildford |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Hyderabad, |
India |
Biotechnology and Drugs |
38.8 |
|
|
|
|
Subsidiary |
New Delhi |
India |
Biotechnology and Drugs |
1.0 |
|
|
|
|
Subsidiary |
Riga |
Latvia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Ho Chi Minh City |
Viet Nam |
Chemical Manufacturing |
|
|
|
|
|
Subsidiary |
Shenzhen |
China |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
San Isidro, Buenos Aires |
Argentina |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Singapore |
Singapore |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Taipei |
Taiwan |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Sofia |
Bulgaria |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Budapest |
Hungary |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Paris |
France |
Miscellaneous Financial Services |
|
|
|
|
|
Subsidiary |
Gentilly |
France |
Biotechnology and Drugs |
14,610.7 |
5,607 |
|
|
|
Subsidiary |
Gentilly |
France |
Chemical Manufacturing |
2,146.6 |
4,271 |
|
|
|
Subsidiary |
Paris |
France |
Chemical Manufacturing |
116.7 |
40 |
|
|
|
Subsidiary |
Milano |
Italy |
Biotechnology and Drugs |
1,884.3 |
2,677 |
|
|
|
Subsidiary |
Anagni, FR |
Italy |
Biotechnology and Drugs |
304.3 |
480 |
|
|
|
Subsidiary |
Milano, Milano |
Italy |
Construction and Agriculture Machinery |
0.0 |
1 |
|
|
|
Subsidiary |
Gouda, Zuid-Holland |
Netherlands |
Miscellaneous Capital Goods |
181.4 |
242 |
|
|
|
Subsidiary |
Veghel, Noord-Brabant |
Netherlands |
Biotechnology and Drugs |
|
27 |
|
|
|
Subsidiary |
Helsinki |
Finland |
Personal and Household Products |
108.2 |
113 |
|
|
|
Subsidiary |
Paris |
France |
Miscellaneous Financial Services |
|
|
|
|
|
Subsidiary |
Santo Domingo |
Dominican Republic |
Chemical Manufacturing |
|
|
|
|
|
Subsidiary |
Mixco |
Guatemala |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Tallinn |
Estonia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Athens |
Greece |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Zagreb |
Croatia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Kyiv |
Ukraine |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Nairobi |
Kenya |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Warsaw |
Poland |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Tashkent |
Uzbekistan |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Algiers |
Algeria |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Paris |
France |
Miscellaneous Financial Services |
|
|
|
|
|
Subsidiary |
Makati City |
Germany |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Panama |
Panama |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Porto Salvo |
Portugal |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Asuncion |
Paraguay |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Bucharest |
Romania |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Ljubljana |
Slovenia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Lumpini, Pathumwan, Bangkok |
Thailand |
Biotechnology and Drugs |
|
|
|
|
|
Joint Venture |
Beijing, Beijing |
China |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Quarry Bay, Hong Kong Island |
Hong Kong |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Casablanca |
Morocco |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Lima |
Peru |
Biotechnology and Drugs |
|
|
|
|
|
Sanofi-Aventis Research & Development |
Subsidiary |
|
|
|
|
|
|
|
Subsidiary |
Bridgewater, NJ |
United States |
Medical Equipment and Supplies |
2,700.0 |
16,508 |
|
|
|
Branch |
Bridgewater, NJ |
United States |
Retail (Drugs) |
91.5 |
500 |
|
|
|
Division |
Kansas City, MO |
United States |
Personal and Household Products |
417.9 |
300 |
|
|
|
Branch |
St Louis, MO |
United States |
Business Services |
12.5 |
90 |
|
|
|
Branch |
Cambridge, MA |
United States |
Retail (Drugs) |
14.6 |
80 |
|
|
|
Branch |
Scottsdale, AZ |
United States |
Personal and Household Products |
44.6 |
32 |
|
|
Executives Report
|
Annual Profit & Loss
|
|
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
|
Period Length |
12 Months |
12 Months |
12 Months |
|
Filed Currency |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.755078 |
0.719047 |
0.683679 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Total income |
14,707.1 |
15,285.2 |
13,908.3 |
|
Net sales |
14,610.7 |
15,172.6 |
13,748.5 |
|
Own work capitalised |
- |
1.3 |
3.3 |
|
Subsidies for operating costs |
1.2 |
0.8 |
1.1 |
|
Supplementary operating income |
106.3 |
277.4 |
199.2 |
|
Other operating income |
19.7 |
23.6 |
16.0 |
|
Other external charges |
2,067.9 |
2,147.6 |
2,628.2 |
|
Cost of goods sold |
8,613.7 |
8,453.4 |
6,293.6 |
|
Taxes and social security costs |
83.8 |
78.2 |
64.5 |
|
Social charges |
195.9 |
202.8 |
211.7 |
|
Total payroll costs |
353.2 |
378.9 |
403.5 |
|
Cost of stock depreciation and amortisation |
123.6 |
111.7 |
- |
|
Fixed asset depreciation and amortisation |
94.3 |
100.4 |
415.4 |
|
Other operating costs |
2,069.6 |
2,798.3 |
2,750.3 |
|
Total operating costs |
13,349.5 |
14,175.7 |
12,711.7 |
|
Net operating income |
1,357.6 |
1,109.5 |
1,196.6 |
|
Total financial income |
118.4 |
98.1 |
15.0 |
|
Interest payable on loans |
16.9 |
12.5 |
- |
|
Other expenses |
113.0 |
89.9 |
4.1 |
|
Total expenses |
129.9 |
102.4 |
4.1 |
|
Profit before tax |
1,346.1 |
1,105.2 |
1,207.5 |
|
Extraordinary income |
27.4 |
83.2 |
51.8 |
|
Extraordinary expenses |
34.7 |
185.7 |
122.6 |
|
Total taxation |
552.1 |
467.2 |
492.6 |
|
Profit distributed to employees |
44.7 |
46.9 |
57.3 |
|
Net profit |
742.0 |
488.6 |
586.7 |
|
Annual Balance
Sheet |
|
Financials in:
USD (mil) |
|
|
|
|
|
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
|
Filed Currency |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.745406 |
0.696986 |
0.719399 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Issued capital |
357.0 |
381.8 |
369.9 |
|
Share premium account |
210.6 |
225.2 |
218.2 |
|
Legal reserves |
114.3 |
106.5 |
98.8 |
|
Total reserves |
51.3 |
54.9 |
53.1 |
|
Profits for the year |
751.6 |
504.1 |
557.5 |
|
Profit brought forward from previous year(s) |
1.1 |
3.0 |
739.8 |
|
Capital subsidies and grants |
0.1 |
0.2 |
0.1 |
|
Total stockholders equity |
1,485.9 |
1,275.5 |
2,037.5 |
|
Provisions and allowances |
317.1 |
338.5 |
343.2 |
|
Trade creditors |
2,578.4 |
3,007.3 |
2,344.0 |
|
Bank loans and overdrafts |
33.2 |
30.7 |
80.7 |
|
Current bank debts |
33.2 |
30.7 |
- |
|
Other loans |
774.3 |
765.8 |
5.5 |
|
Other liabilities |
72.0 |
84.2 |
302.2 |
|
Debts on fixed assets |
13.8 |
15.6 |
15.4 |
|
Income stated in advance |
2.2 |
3.4 |
1.1 |
|
Taxation and social security |
783.0 |
690.1 |
679.2 |
|
Total current liabilities |
4,255.2 |
4,591.8 |
- |
|
Total debts |
4,256.9 |
4,597.1 |
3,428.1 |
|
Regularisation account |
43.6 |
37.3 |
95.4 |
|
Total liabilities (including net worth) |
6,103.5 |
6,248.3 |
5,904.1 |
|
Patents |
6.4 |
10.1 |
11.2 |
|
Goodwill |
- |
- |
14.5 |
|
Other intangibles |
3.7 |
0.6 |
2.8 |
|
Land |
22.0 |
21.7 |
19.7 |
|
Buildings |
255.4 |
267.7 |
233.8 |
|
Other fixed assets |
434.1 |
472.0 |
453.4 |
|
Long-term investments |
0.1 |
0.0 |
0.2 |
|
Other financial assets |
6.1 |
6.4 |
6.4 |
|
Total non-current assets |
727.8 |
778.6 |
742.0 |
|
Prepayments |
0.9 |
1.7 |
2.6 |
|
Net stocks and work in progress |
1,038.3 |
868.9 |
805.8 |
|
Trade debtors |
3,042.0 |
3,497.6 |
3,023.0 |
|
Other receivables |
1,184.3 |
990.0 |
1,118.0 |
|
Prepaid expenses |
43.8 |
42.4 |
39.2 |
|
Cash and liquid assets |
22.3 |
27.5 |
83.0 |
|
Total current assets |
5,331.5 |
5,428.1 |
5,071.6 |
|
Prepaid expenses and deferred costs |
44.3 |
41.6 |
90.5 |
|
Total assets |
6,103.5 |
6,248.3 |
5,904.1 |
|
|
|
Annual Ratios |
|
Financials in: USD
(mil) |
|
|
|
|
|
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
|
Period Length |
12 Months |
12 Months |
12 Months |
|
Filed Currency |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.745406 |
0.696986 |
0.719399 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Current ratio |
1.30 |
1.20 |
- |
|
Quick ratio |
1.00 |
1.00 |
- |
|
Total liabilities to net worth |
2.97% |
3.76% |
1.79% |
|
Net worth to total assets |
0.24% |
0.20% |
0.33% |
|
Collection period |
62.40 |
67.80 |
70.20 |
|
Stock turnover rate |
14.30 |
18.00 |
16.20 |
|
Asset turnover |
2.43% |
2.51% |
2.21% |
|
Profit margin |
0.09% |
0.07% |
0.09% |
|
Return on assets |
0.22% |
0.18% |
0.19% |
|
Shareholders' return |
0.95% |
0.93% |
0.60% |
|
Sales per employee |
13,224.93 |
12,763.30 |
10,682.11 |
|
Profit per employee |
1,218.41 |
929.70 |
938.19 |
|
Average wage per employee |
319.67 |
318.71 |
313.50 |
|
Net worth |
1,485.9 |
1,275.5 |
2,037.5 |
|
Number of employees |
5,472 |
5,607 |
5,772 |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.50.59 |
|
|
1 |
Rs.80.34 |
|
Euro |
1 |
Rs.67.14 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SCs credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.